# Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

> **NCT00215501** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 54 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Irinotecan
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00215501
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-09
- **Final completion:** 2008-09
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-11-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00215501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00215501, "Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00215501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*